BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma

BRAF inhibitor (BRAFi) has been used for treatment of melanomas harboring V600E mutation. Despite a high initial response rate, resistance to BRAFi is inevitable. Here, we demonstrate that BRAFi-resistant (BR) melanomas are susceptible to arginine deprivation due to inability to initiate re-expressi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Li, Ying-Ying, Wu, Chunjing, Chen, Shu-Mei, Shah, Sumedh S., Wangpaichitr, Medhi, Feun, Lynn G., Kuo, Macus T., Suarez, Miguel, Prince, Jeffrey, Savaraj, Niramol
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4951241/
https://ncbi.nlm.nih.gov/pubmed/26771234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6882
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki